research Finasteride blocks progesterone synthesis in MA-10 Leydig tumor cells.
Finasteride blocks progesterone production in specific tumor cells, potentially causing side effects.
Search
for
Sort by
Research
540-570 / 1000+ results 
research A model for the turnover of dihydrotestosterone in the presence of the irreversible 5α-reductase inhibitors GI198745 and finasteride
Both drugs lower DHT levels, with GI198745 being more effective.
research Respiratory regulation by steroids in newborn rats: a sex‐specific balance between allopregnanolone and progesterone receptors
Breathing in newborn rats is affected differently by hormones based on their sex.
research Luncheon Symposium (LS) : Update on the efficacy and safety of dutasteride in the management of androgenetic alopecia
Dutasteride is effective and safe for treating common hair loss, and it's more potent than finasteride, leading to better hair growth and thickness.
research A multifunctional cholesterol-free liposomal platform based on protopanaxadiol for alopecia therapy
A cholesterol-free liposomal platform using protopanaxadiol effectively promotes hair growth and treats alopecia.
research SRD5A2 and emerging therapies in androgen-driven disorders
research Finasteride
Finasteride treats enlarged prostate, shrinks it, improves urination, but may cause sexual dysfunction and isn't for women or children.
research Dutasteride: A Review of its Use in the Management of Prostate Disorders
Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
research Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons
GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.
research Diphenylcyclopropenone in severe alopecia areata in children and adolescents: long-term follow-up and relapse rate
Diphenylcyclopropenone is effective and safe for treating severe alopecia areata in children, with maintenance therapy reducing relapse risk.
research Post-Drug Syndromes: A Neglected Challenge in Pharmacovigilance and Public Health
Current drug safety systems fail to detect long-term side effects, leading to preventable health issues.
research Valproic Acid is an Effective Anti-Emetic Treatment in Alexander Disease (P10-9.010)
Valproic acid is a more effective treatment for vomiting in Alexander disease than other medications, with few side effects.
research Treatment Response to Diphenylcyclopropenone in Patients with Alopecia Totalis/Universalis
DPCP can help regrow hair in some people with severe alopecia.
research Five‐year experience in the treatment of alopecia areata with DPC
Diphencyprone (DPC) is an effective and safe long-term treatment for alopecia areata, especially with maintenance therapy.
research A Novel In Vivo Active Pemphigus Model Targeting Desmoglein1 and Desmoglein3: A Tool Representing All Pemphigus Variants
New mouse models of Pemphigus show severe symptoms and need better treatments.
research Trazodone and chlorpromazine a proposal treatment for syndrome post-finasteride and syndrome of post-selective serotonin reuptake inhibitors (post-SSRI)
Trazodone and Chlorpromazine might help treat sexual dysfunction from finasteride and SSRIs.
research Parquetina nigrescens in the Management of Polyendocrine Metabolic Ovarian Syndrome: Therapeutic Potential, Mechanistic Insights, and Future Perspectives
Parquetina nigrescens may help manage PCOS by improving ovarian function and insulin sensitivity.
research Evaluation of Therapeutic Potential of a Selective 5α-reductase Inhibitor against Glioblastoma: Molecular Docking and In Vitro Insights
research Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study
GLP1-RAs may have higher reports of suicidal events and hair loss compared to other diabetes drugs.
research Finasteride
Finasteride treats enlarged prostate, improves urinary flow, but may cause sexual side effects.
research Polygenic risk score predicting susceptibility and outcome of benign prostatic hyperplasia in the Han Chinese
Polygenic risk scores can predict the risk and outcomes of benign prostatic hyperplasia.
research Modificazioni nella funzionalità , nell'espressione dei recettori GABAA extrasinaptici e nella plasticità sinaptica nell'ippocampo di ratto durante la gravidanza e dopo il parto.
During late pregnancy in rats, hormonal changes increased certain GABAA receptors in specific brain cells.
research Synthesis and application of clinically approved small-molecule drugs targeting androgen receptor
Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.
research Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts
Steroidogenesis inhibitors change but don't stop androgen production in prostate cancer.
research LPA3, a unique G protein-coupled receptor for lysophosphatidic acid
LPA3 is crucial for embryo implantation and links LPA to prostaglandin signaling.
research Lower Urinary Tract Symptoms: What’s New in Medical Treatment?
New drugs and combination therapies are improving treatment for lower urinary tract symptoms.
research Protoporphyrin IX: the Good, the Bad, and the Ugly
Protoporphyrin IX is useful in cancer treatment but can cause health problems if not properly regulated.
research Regulation of immune response genes in the skin of allergic and clinically tolerant individuals exposed to p‐phenylenediamine
Everyone has an immune response to PPD, but reactions differ, causing tolerance, mild inflammation, or allergy.
research High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia
Older patients sticking to their prostate medication saw lasting health benefits.
research Three-Month Treatment With a Long-Acting Gonadotropin-Releasing Hormone Agonist of Patients With Benign Prostatic Hyperplasia: Effects on Tissue Androgen Concentration, 5α-Reductase Activity and Androgen Receptor Content*
A three-month treatment with a GnRH agonist significantly lowered androgen levels and 5α-reductase activity in men with benign prostatic hyperplasia.